Tech Company Inital Public Offerings

Precision BioSciences IPO

Precision BioSciences, based in Durham, debuted as a public company on 3/27/2019.

Transaction Overview

Announced On
Transaction Type
Proceeds Purpose
Proceeds will be used as follows: approximately $7.0 to $9.0 million to initiate and complete a Phase 1/2a clinical trial for our CD19 CAR T cell product candidate; approximately $50.0 to $52.0 million to advance and expand the development of our other CAR T cell product candidates and allogeneic CAR T immunotherapy platform, including to submit an IND for each of our CD20, BCMA and CLL-1 CAR T cell product candidates; approximately $18.0 to $20.0 million to advance and expand the preclinical development of our in vivo gene correction platform, including early discovery efforts, chemistry, manufacturing and controls, or CMC, and IND-enabling studies; approximately $12.0 to $14.0 million to fund the build-out of our planned cGMP-compliant manufacturing facility; and the remainder to fund new and ongoing research and development activities, to fund the portion of expenses we are responsible for with respect to the development of our food platform and for working capital and other general

Company Information

Company Status
Mailing Address
302 East Pettigrew St. Dibrell Building A-100
Durham, NC 27701
Email Address
The Precision BioSciences (Nasdaq: DTIL) mission is to translate the world's most powerful genome editing technology into greatly needed products throughout the life sciences.
Precision BioSciences LinkedIn Company Profile
Social Media
Precision BioSciences Company Twitter Account
Company News
Precision BioSciences News
Precision BioSciences on Facebook
Precision BioSciences on YouTube

Management Team

Email & Social
Chief Executive Officer
Matthew Kane
  Matthew Kane LinkedIn Profile  Matthew Kane Twitter Account  Matthew Kane News  Matthew Kane on Facebook
Chief Scientific Officer
Derek Jantz
  Derek Jantz LinkedIn Profile  Derek Jantz Twitter Account  Derek Jantz News  Derek Jantz on Facebook
Vice President
Clayton Beard
  Clayton Beard LinkedIn Profile  Clayton Beard Twitter Account  Clayton Beard News  Clayton Beard on Facebook
VP - Bus. Development
Drew Applefield
  Drew Applefield LinkedIn Profile  Drew Applefield Twitter Account  Drew Applefield News  Drew Applefield on Facebook
VP - Bus. Development
Michael Dombeck
  Michael Dombeck LinkedIn Profile  Michael Dombeck Twitter Account  Michael Dombeck News  Michael Dombeck on Facebook
VP - Engineering
Victor Bartsevich
  Victor Bartsevich LinkedIn Profile  Victor Bartsevich Twitter Account  Victor Bartsevich News  Victor Bartsevich on Facebook
VP - Finance
Abid Ansari
  Abid Ansari LinkedIn Profile  Abid Ansari Twitter Account  Abid Ansari News  Abid Ansari on Facebook
VP - Marketing
Heather King
  Heather King LinkedIn Profile  Heather King Twitter Account  Heather King News  Heather King on Facebook
VP - Operations
Sinu Bhandaru
  Sinu Bhandaru LinkedIn Profile  Sinu Bhandaru Twitter Account  Sinu Bhandaru News  Sinu Bhandaru on Facebook
VP - Regulatory Affairs
Marcia Gaido
  Marcia Gaido LinkedIn Profile  Marcia Gaido Twitter Account  Marcia Gaido News  Marcia Gaido on Facebook



Browse more venture capital transactions:

Prev: 3/27/2019: Vlocity venture capital transaction
Next: 3/27/2019: venture capital transaction


Share this article


About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. All VC database entries reported here come from publicly available VC deal announcements. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary